If Anavex know they have a game changer Alzheimer drug, they know they will be trading higher to meet uplisting requirements. Also, may have a partnership deal, which would also cause pps to surge higher which will help them meet uplisting requirements.
You know what? I really don't care. I would vote for an R/S to achieve uplisting and institutional investment goals in a heartbeat. It won't even be a part of the equation for 2 years, unless we're real lucky. That's how I look at it...lucky to be facing the needs that a R/S would facilitate. I've called it a non-issue for an emerging OTC biotech enough times. I don't think Dr Missling is counting on his last milestone occurring anytime soon. Let's talk about current things :-D
As I follow events that occur along the timeline of the company's updates, I would expect this updated balance sheet to indicate we are ready to incur the expense of an IND for epilepsy. I'm sure Dr French is eagerly awaiting her contribution.
I think today's 1.30 buyers will be pleasantly surprised come Thursday. Friday will be another for the books. GLTA §AVXL
News 
Market Data 
Discover 
